Treatment of premenopausal patients with advanced or recurrent breast cancer by chemical ablation / 中国医学科学院学报
Acta Academiae Medicinae Sinicae
;
(6): 60-62, 2003.
Artigo
em Chinês
| WPRIM
| ID: wpr-301898
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the clinical efficacy and safety of luteinizing hormone releasing hormone (LH-RH) analog in premenopausal patients with advanced or recurrent breast cancer.</p><p><b>METHODS</b>LH-RH analog (enantone 3.75 mg/2 ml) were administered to 28 premenopausal patients with advanced recurrent breast cancer and its efficacy and side effect were observed.</p><p><b>RESULTS</b>The response rate (complete response and partial response) was 42.9%, and after 8 weeks of treatment, the plasma estrogen in all patients decreased to the level of postmenopause. No major adverse events were observed.</p><p><b>CONCLUSIONS</b>LH-RH analog is effective and safe for premenopausal breast cancer with low adverse reaction and its administration method is easy.</p>
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Sangue
/
Neoplasias da Mama
/
Hormônio Luteinizante
/
Hormônio Liberador de Gonadotropina
/
Leuprolida
/
Pré-Menopausa
/
Usos Terapêuticos
/
Tratamento Farmacológico
/
Estrogênios
/
Recidiva Local de Neoplasia
Limite:
Adulto
/
Feminino
/
Humanos
Idioma:
Chinês
Revista:
Acta Academiae Medicinae Sinicae
Ano de publicação:
2003
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS